Thai medical firm Siam Bioscience, owned by the King Maha Vajiralongkorn, reported a near 50-fold increase in annual profit in 2021, when it began producing AstraZeneca Plc’s COVID-19 vaccine.
According to Thai’s Department of Business Development Ministry of Commerce, the firm’s profit significantly rose up to 4,650% to 1.69 billion baht and revenues increased by 1,500% to a record 4.9 billion baht, aided by its contract to manufacture 200 million doses of the Anglo-Swedish firm’s COVID-19 vaccine.
The company’s business improved remarkably last year as it began manufacturing vaccines for the first time.
Siam Bioscience was first established in 2009 by the late King Bhumibol Adulyadej to produce biopharmaceuticals and improve public health.
Source:
- https://brandinside.asia/siam-bioscience-co-ltd-profit-jumped-almost-4700/
- https://www.reuters.com/business/healthcare-pharmaceuticals/thai-kings-medical-firm-reports-record-profit-after-vaccine-deal-with-2022-08-25/
Related posts:
Thailand signed agreement with AstraZeneca to secure COVID-19 vaccine
Thailand secures 63 million doses Covid-19 vaccine with vaccinations scheduled to start next month
ABB contributing to accelerate COVID-19 vaccine development in Thailand.
Thailand DDC and AstraZeneca Thailand update on Covid-19 vaccine
